NeuroBytes: Key Features of Lecanemab
Course Description
In the past few years, there have been many clinical trials for anti-amyloid agents for Alzheimer’s Disease. In 2023, Lecanemab gained FDA approval for mild cognitive impairment and mild dementia in Alzheimer’s disease. The purpose of this video is to help providers understand the mechanism of action, requirements for initiation, side effects of administration, and contraindications of this medication.
Learning Objectives
As a result of this program the learner will be able to:
- Understand the clinical indication and prerequisites for Lecanemab
- Know the side effects and contraindications of this medication
Date of Release
January 12, 2024
Confidentiality of Data
All material © American Academy of Neurology Institute unless otherwise indicated. All rights reserved. See complete
Terms of Use.
Faculty & Disclosures
MAYA GATTUPALLI, DO
Neurology Resident
The University of Arizona-Phoenix
Phoenix, AZ
*Dr. Gattupalli has nothing to disclose.
Editor
Reviewer
Neurology Resident
The University of Arizona-Phoenix
Phoenix, AZ
*Dr. Gattupalli has nothing to disclose.
Editor
ANELYSSA D'ABREU, MD, PhD, MPH
Assistant Professor of Neurology
University of Virginia
Charlottesville, VA
*The institution of Dr. D'Abreu has received research support from Alzheimer's and Related Diseases Research Award Fund (Virginia Center on Aging in the College of Health Professions). Dr. D'Abreu has received personal compensation in the range of $500-$4,999 for serving as a Lecturer with Primed.
Reviewer
CALLI LEIGHANN COOK, DNP, FNP-C
Clinical Assistnat Professor, Emory Nell Hodgson
Woodruff School of Nursing
Nurse Practitioner, Emory Brain Health Center
Atlanta, GA
*Dr. Cook has nothing to disclose.
Voiceover Artist
BEN STODDART
Senior Trainee Education Administrator
Minneapolis, MN
*Mr. Stoddart has nothing to disclose.
NeuroBytes Staff
Xiaoyu Sun, Associate Director, eLearning
Minneapolis, MN
*Ms. Sun has nothing to disclose.
Robert Rook, eLearning Manager
Minneapolis, MN
*Mr. Rook has nothing to disclose.
Zach Cramer, eLearning Program Manager
Minneapolis, MN
*Mr. Cramer has nothing to disclose.